Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $57.00

Plus Therapeutics (NASDAQ:PSTV) had its target price reduced by investment analysts at Ascendiant Capital Markets from $65.00 to $57.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other analysts have also issued reports on PSTV. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.40.

Plus Therapeutics Price Performance

Shares of PSTV stock opened at $5.41 on Monday. The stock has a market cap of $37.24 million, a price-to-earnings ratio of -2.35 and a beta of 1.38. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The firm’s 50 day moving average price is $5.66 and its two-hundred day moving average price is $8.61.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. On average, equities analysts forecast that Plus Therapeutics will post -3.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Several institutional investors have recently bought and sold shares of PSTV. Susquehanna International Group LLP acquired a new stake in Plus Therapeutics in the 3rd quarter valued at about $46,000. Jane Street Group LLC acquired a new stake in Plus Therapeutics in the 2nd quarter valued at about $41,000. State Street Corp lifted its holdings in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares during the last quarter. Scientech Research LLC acquired a new stake in Plus Therapeutics in the 3rd quarter valued at about $100,000. Finally, XTX Topco Ltd acquired a new stake in Plus Therapeutics in the 4th quarter valued at about $127,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.